Emapalumab (NI-0501) 是一种人源化 IgG1 单克隆抗体，可非竞争性地抑制IFN-γ。Emapalumab 与游离的 IFN-γ 以及与其受体结合的 IFN-γ 具有高亲和力 (Kd=1.4 pM)。Emapalumab 可用于噬血细胞性淋巴组织细胞增多症 (HLH) 的研究。
| 生物活性 | Emapalumab (NI-0501) is a humanized monoclonalIgG1antibody that noncompetitively inhibitsIFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both freeIFN-γas well asIFN-γbound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH)[1]. |
体外研究
(In Vitro) | Emapalumab (NI-0501) impairs IFNcR1 and IFNc-Receptor-2 (IFNcR2) interaction induced by IFNc at the cell surface.
|
| Clinical Trial | |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
